Efficacy of etanercept for wear debris-induced osteolysis

Journal of Bone and Mineral Research

Volumn 16, Issue 2, 2001, Pages 338-347

  Childs, Lisa M ^a   Goater, J Jeffrey ^a   O’keefe, Regis J ^b   Schwarz, Edward M ^b  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b NONE

Author keywords

Aseptic loosening; Etanercept; Osteolysis; Tumor necrosis factor

Indexed keywords

ETANERCEPT; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ARTHROPLASTY; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG MECHANISM; JOINT PROSTHESIS; MACROPHAGE; MOUSE; NONHUMAN; OSTEOLYSIS; PHAGOCYTOSIS; PROSTHESIS LOOSENING;

EID: 0035143798     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/jbmr.2001.16.2.338     Document Type: Article

References (52)

1. The problem in total joint arthroplasty: Aseptic loosening
2. The problem is osteolysis
3. Charnley total hip arthroplasty in patients less than fifty years old. A twenty to twenty-five-year follow-up note
4. Outcome of Charnley total hip replacement across a single health region in England: The results at five years from a regional hip register
5. Primary total hip arthroplasty with a cementless porous-coated anatomic total hip prosthesis: 10- to 12-year results of prospective and consecutive series
6. Results of revision for mechanical failure after cemented total hip replacement, 1979 to 1982. A two to five-year follow-up
7. A comparison of primary and revision total knee arthroplasty using the kinematic stabilizer prosthesis
8. Effect of size, concentration, surface area, and volume of polymethylmethacrylate particles on human macrophages in vitro
9. Ultrahigh molecular weight polyethylene particles have direct effects on proliferation, differentiation, and local factor production of MG63 osteoblast-like cells
10. Response of three murine macrophage populations to particulate debris: Bone resorption in organ cultures
11. Mechanisms of cellular recruitment in aseptic loosening of prosthetic joint implants
12. Human monocyte response to particulate biomaterials generated in vivo and in vitro
13. Titanium, chromium and cobalt ions modulate the release of bone-associated cytokines by human monocytes/macrophages in vitro
14. Modulation of the production of cytokines in titanium-stimulated human peripheral blood monocytes by pharmacological agents. The role of cAMP-mediated signaling mechanisms
15. Human monocyte/macrophage response to cobalt-chromium corrosion products and titanium particles in patients with total joint replacements
16. Measurement and removal of adherent endotoxin from titanium particles and implant surfaces
17. The synovial-like membrane at the bone-cement interface in loose total hip replacements and its proposed role in bone lysis
18. Formation of a synovial-like membrane at the bone-cement interface. Its role in bone resorption and implant loosening after total hip replacement
19. Cellular mediators secreted by interfacial membranes obtained at revision total hip arthroplasty
20. Anti-TNFa therapy as a clinical intervention for periprosthetic osteolysis
21. Stimulation of bone resorption and inhibition of bone formation in vitro by human tumour necrosis factors
22. Prostaglandin E2, interleukin 1 alpha, and tumor necrosis factor-alpha increase human osteoclast formation and bone resorption in vitro
23. Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction
24. Increased levels of tumor necrosis factor-alpha and interleukin-6 protein and messenger RNA in human peripheral blood monocytes due to titanium particles
25. Interleukin-1 production by activated macrophages surrounding loosened orthopaedic implants: A potential role in osteolysis
26. Bone formation and bone resorption in failed total joint arthroplasties: Histomorphometric analysis with histochemical and immunohistochemical technique
27. Tumor necrosis factor-alpha mediates orthopedic implant osteolysis
28. TNF-a/NFkB signaling in periprosthetic osteolysis
29. Biological response modifiers may yield a new class of drugs to treat arthritis
30. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein
31. Rheumatoid arthritis
32. A phase III trial of etanercept vs. methotrexate (MTX) in early rheumatoid arthritis
33. 54-week clinical and radiolgraphic results from the attract trial: A phase III study of infliximab (Remicade) in patients with active RA despite methotrexate
34. A quantitative small animal surrogate to evaluate drug efficacy in preventing wear debris-induced osteolysis
35. Immunological defects in mice with a targeted disruption in Bcl-3
36. Transgenic mice expressing human tumour necrosis factor: A predictive genetic model of arthritis
37. TNF-alpha as a therapeutic target in rheumatoid arthritis
38. Influence of a recombinant human soluble tumor necrosis factor receptor FC fusion protein on type II collagen-induced arthritis in mice
39. Macrophage activation and migration in interface tissue around loosening total hip arthroplasty components
40. Tumor necrosis factor-alpha (TNF-alpha) in loosening of total hip replacement (THR)
41. Monoclonal anti-TNF-alpha antibody as a probe of pathogenesis and therapy of rheumatoid disease
42. A new mechanism of bone destruction in rheumatoid arthritis: Synovial fibroblasts induce osteoclastogenesis
43. Osteoclastic activation is the principal mechanism leading to secondary osteoporosis in rheumatoid arthritis
44. Regulation of osteoclast activity
45. Mice deficient for the 55 kd tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to L. monocytogenes infection
46. Defective Peyer's patch organogenesis in mice lacking the 55-kD receptor for tumor necrosis factor
47. Tumour necrosis factor alpha gene polymorphisms in rheumatoid arthritis: Association with susceptibility to, or severity of disease?
48. Functional analysis of a human tumor necrosis factor alpha (TNF-alpha) promoter polymorphism related to joint damage in rheumatoid arthritis
49. Distribution of four polymorphisms in the tumour necrosis factor (TNF-) genes in patients with inflammatory bowel disease (IBD)
50. Association of TNF-2, a TNF-alpha promoter polymorphism, with septic shock susceptibility and mortality: A multicenter study
51. Osteoclast differentiation factor acts as a multifunctional regulator in murine osteoclast differentiation and function
52. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL